The study will be offered at the European Breasts Cancer Conference Thursday 25th March.

John Bartlett, Professor of Molecular Pathology at the University of Edinburgh , said: ‘Our aim was to identify individuals for whom anthracyclines offered benefit when it comes to disease control and improved survival, and to seek to make sure that future treatment was geared to this group. Our finding that individuals whose tumours possess the CEP17 abnormality will react to anthracyclines is entirely novel. Subject to confirmation, this shows that only those individuals with CEP17 tumours should receive anthracyclines, thereby enabling other individuals who do not have the CEP17 abnormality in order to avoid a toxic treatment that won’t be effective.’ Related StoriesSausages With Antioxidants From Berries To Prevent CancerNew RNA check of blood platelets can be used to detect area of cancerFDA grants accelerated authorization for Tagrisso to treat patients with advanced NSCLCCEP17 is usually on the same chromosome as two additional genes known to be involved with breast cancer, HER2 and TOP2A, but the researchers did not find any significant associations between them and response to anthracycline treatment.Larsson concluded The beneficial effect of chocolate intake on stroke may be linked to the flavonoids in chocolate. Flavonoids look like protective against coronary disease through antioxidant, anti-inflammatory and anti-clotting properties. It’s also feasible that flavonoids in chocolate may reduce blood concentrations of bad cholesterol and reduce blood circulation pressure. Many prior studies including cocoa and chocolate intake determined that dark chocolate sources were most beneficial. This study discovered that the sort of chocolate consumed was not one factor and conferred the same outcomes regardless of cocoa content. Nutrition professionals still recommend consuming chocolates with an 85 % coca content to avoid excessive dietary sugar and significantly lower threat of stroke and cardiovascular disease.

Lisa Rosenbaum, M.D.: Transitional Chaos or Enduring Harm? The EHR and the Disruption of Medicine A decade ago, a primary care physician We admired seemed to come undone.